[
  {
    "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
    "bbox": [
      180,
      467,
      898,
      482
    ],
    "label": 4,
    "category": "Effective Date"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      610,
      141,
      722,
      152
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      596,
      157,
      741,
      168
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
    "bbox": [
      181,
      189,
      1000,
      203
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "time to time, and the regulations promulgated thereunder..",
    "bbox": [
      112,
      208,
      591,
      223
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
    "bbox": [
      179,
      242,
      1000,
      259
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
    "bbox": [
      112,
      264,
      1000,
      277
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
    "bbox": [
      111,
      282,
      1000,
      297
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
    "bbox": [
      114,
      303,
      1000,
      316
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
    "bbox": [
      112,
      321,
      941,
      334
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
    "bbox": [
      179,
      355,
      1000,
      370
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
    "bbox": [
      111,
      375,
      1000,
      390
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
    "bbox": [
      110,
      395,
      1000,
      409
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
    "bbox": [
      112,
      414,
      1000,
      428
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
    "bbox": [
      111,
      432,
      843,
      447
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
    "bbox": [
      180,
      467,
      898,
      482
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
    "bbox": [
      181,
      504,
      820,
      517
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
    "bbox": [
      180,
      540,
      1000,
      554
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
    "bbox": [
      112,
      559,
      1000,
      574
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
    "bbox": [
      111,
      579,
      1000,
      593
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "the Product with regard to Target Professionals in the Specialty",
    "bbox": [
      111,
      597,
      647,
      612
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
    "bbox": [
      179,
      632,
      1000,
      647
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
    "bbox": [
      114,
      654,
      1000,
      666
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
    "bbox": [
      111,
      690,
      1000,
      705
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
    "bbox": [
      111,
      709,
      1000,
      724
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
    "bbox": [
      112,
      729,
      1000,
      742
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
    "bbox": [
      111,
      747,
      1000,
      761
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
    "bbox": [
      111,
      767,
      1000,
      781
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
    "bbox": [
      113,
      787,
      1000,
      799
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
    "bbox": [
      111,
      803,
      1000,
      820
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "2",
    "bbox": [
      660,
      856,
      671,
      867
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
    "bbox": [
      150,
      931,
      1000,
      941
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "bbox": [
      415,
      944,
      918,
      953
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      593,
      1000
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      610,
      141,
      722,
      152
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      596,
      157,
      741,
      168
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
    "bbox": [
      181,
      189,
      1000,
      203
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "time to time, and the regulations promulgated thereunder..",
    "bbox": [
      112,
      208,
      591,
      223
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
    "bbox": [
      179,
      242,
      1000,
      259
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
    "bbox": [
      112,
      264,
      1000,
      277
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
    "bbox": [
      111,
      282,
      1000,
      297
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
    "bbox": [
      114,
      303,
      1000,
      316
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
    "bbox": [
      112,
      321,
      941,
      334
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
    "bbox": [
      179,
      355,
      1000,
      370
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
    "bbox": [
      111,
      375,
      1000,
      390
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
    "bbox": [
      110,
      395,
      1000,
      409
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
    "bbox": [
      112,
      414,
      1000,
      428
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
    "bbox": [
      111,
      432,
      843,
      447
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
    "bbox": [
      180,
      467,
      898,
      482
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
    "bbox": [
      181,
      504,
      820,
      517
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
    "bbox": [
      180,
      540,
      1000,
      554
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
    "bbox": [
      112,
      559,
      1000,
      574
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
    "bbox": [
      111,
      579,
      1000,
      593
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "the Product with regard to Target Professionals in the Specialty",
    "bbox": [
      111,
      597,
      647,
      612
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
    "bbox": [
      179,
      632,
      1000,
      647
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
    "bbox": [
      114,
      654,
      1000,
      666
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
    "bbox": [
      111,
      690,
      1000,
      705
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
    "bbox": [
      111,
      709,
      1000,
      724
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
    "bbox": [
      112,
      729,
      1000,
      742
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
    "bbox": [
      111,
      747,
      1000,
      761
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
    "bbox": [
      111,
      767,
      1000,
      781
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
    "bbox": [
      113,
      787,
      1000,
      799
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
    "bbox": [
      111,
      803,
      1000,
      820
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "2",
    "bbox": [
      660,
      856,
      671,
      867
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
    "bbox": [
      150,
      931,
      1000,
      941
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "bbox": [
      415,
      944,
      918,
      953
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      593,
      1000
    ],
    "label": 10,
    "category": "Non-Compete"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      610,
      141,
      722,
      152
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      596,
      157,
      741,
      168
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
    "bbox": [
      181,
      189,
      1000,
      203
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "time to time, and the regulations promulgated thereunder..",
    "bbox": [
      112,
      208,
      591,
      223
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
    "bbox": [
      179,
      242,
      1000,
      259
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
    "bbox": [
      112,
      264,
      1000,
      277
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
    "bbox": [
      111,
      282,
      1000,
      297
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
    "bbox": [
      114,
      303,
      1000,
      316
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
    "bbox": [
      112,
      321,
      941,
      334
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
    "bbox": [
      179,
      355,
      1000,
      370
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
    "bbox": [
      111,
      375,
      1000,
      390
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
    "bbox": [
      110,
      395,
      1000,
      409
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
    "bbox": [
      112,
      414,
      1000,
      428
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
    "bbox": [
      111,
      432,
      843,
      447
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
    "bbox": [
      180,
      467,
      898,
      482
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
    "bbox": [
      181,
      504,
      820,
      517
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
    "bbox": [
      180,
      540,
      1000,
      554
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
    "bbox": [
      112,
      559,
      1000,
      574
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
    "bbox": [
      111,
      579,
      1000,
      593
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "the Product with regard to Target Professionals in the Specialty",
    "bbox": [
      111,
      597,
      647,
      612
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
    "bbox": [
      179,
      632,
      1000,
      647
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
    "bbox": [
      114,
      654,
      1000,
      666
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
    "bbox": [
      111,
      690,
      1000,
      705
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
    "bbox": [
      111,
      709,
      1000,
      724
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
    "bbox": [
      112,
      729,
      1000,
      742
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
    "bbox": [
      111,
      747,
      1000,
      761
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
    "bbox": [
      111,
      767,
      1000,
      781
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
    "bbox": [
      113,
      787,
      1000,
      799
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
    "bbox": [
      111,
      803,
      1000,
      820
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "2",
    "bbox": [
      660,
      856,
      671,
      867
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
    "bbox": [
      150,
      931,
      1000,
      941
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "bbox": [
      415,
      944,
      918,
      953
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      593,
      1000
    ],
    "label": 13,
    "category": "No-Solicit Of Employees"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      610,
      141,
      722,
      152
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      596,
      157,
      741,
      168
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
    "bbox": [
      181,
      189,
      1000,
      203
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "time to time, and the regulations promulgated thereunder..",
    "bbox": [
      112,
      208,
      591,
      223
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
    "bbox": [
      179,
      242,
      1000,
      259
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
    "bbox": [
      112,
      264,
      1000,
      277
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
    "bbox": [
      111,
      282,
      1000,
      297
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
    "bbox": [
      114,
      303,
      1000,
      316
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
    "bbox": [
      112,
      321,
      941,
      334
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
    "bbox": [
      179,
      355,
      1000,
      370
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
    "bbox": [
      111,
      375,
      1000,
      390
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
    "bbox": [
      110,
      395,
      1000,
      409
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
    "bbox": [
      112,
      414,
      1000,
      428
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
    "bbox": [
      111,
      432,
      843,
      447
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
    "bbox": [
      180,
      467,
      898,
      482
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
    "bbox": [
      181,
      504,
      820,
      517
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
    "bbox": [
      180,
      540,
      1000,
      554
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
    "bbox": [
      112,
      559,
      1000,
      574
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
    "bbox": [
      111,
      579,
      1000,
      593
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "the Product with regard to Target Professionals in the Specialty",
    "bbox": [
      111,
      597,
      647,
      612
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
    "bbox": [
      179,
      632,
      1000,
      647
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
    "bbox": [
      114,
      654,
      1000,
      666
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
    "bbox": [
      111,
      690,
      1000,
      705
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
    "bbox": [
      111,
      709,
      1000,
      724
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
    "bbox": [
      112,
      729,
      1000,
      742
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
    "bbox": [
      111,
      747,
      1000,
      761
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
    "bbox": [
      111,
      767,
      1000,
      781
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
    "bbox": [
      113,
      787,
      1000,
      799
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
    "bbox": [
      111,
      803,
      1000,
      820
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "2",
    "bbox": [
      660,
      856,
      671,
      867
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
    "bbox": [
      150,
      931,
      1000,
      941
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "bbox": [
      415,
      944,
      918,
      953
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      593,
      1000
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      610,
      141,
      722,
      152
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      596,
      157,
      741,
      168
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
    "bbox": [
      181,
      189,
      1000,
      203
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "time to time, and the regulations promulgated thereunder..",
    "bbox": [
      112,
      208,
      591,
      223
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
    "bbox": [
      179,
      242,
      1000,
      259
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
    "bbox": [
      112,
      264,
      1000,
      277
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
    "bbox": [
      111,
      282,
      1000,
      297
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
    "bbox": [
      114,
      303,
      1000,
      316
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
    "bbox": [
      112,
      321,
      941,
      334
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
    "bbox": [
      179,
      355,
      1000,
      370
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
    "bbox": [
      111,
      375,
      1000,
      390
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
    "bbox": [
      110,
      395,
      1000,
      409
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
    "bbox": [
      112,
      414,
      1000,
      428
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
    "bbox": [
      111,
      432,
      843,
      447
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
    "bbox": [
      180,
      467,
      898,
      482
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
    "bbox": [
      181,
      504,
      820,
      517
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
    "bbox": [
      180,
      540,
      1000,
      554
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
    "bbox": [
      112,
      559,
      1000,
      574
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
    "bbox": [
      111,
      579,
      1000,
      593
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "the Product with regard to Target Professionals in the Specialty",
    "bbox": [
      111,
      597,
      647,
      612
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
    "bbox": [
      179,
      632,
      1000,
      647
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
    "bbox": [
      114,
      654,
      1000,
      666
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
    "bbox": [
      111,
      690,
      1000,
      705
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
    "bbox": [
      111,
      709,
      1000,
      724
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
    "bbox": [
      112,
      729,
      1000,
      742
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
    "bbox": [
      111,
      747,
      1000,
      761
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
    "bbox": [
      111,
      767,
      1000,
      781
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
    "bbox": [
      113,
      787,
      1000,
      799
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
    "bbox": [
      111,
      803,
      1000,
      820
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "2",
    "bbox": [
      660,
      856,
      671,
      867
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
    "bbox": [
      150,
      931,
      1000,
      941
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "bbox": [
      415,
      944,
      918,
      953
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      593,
      1000
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      610,
      141,
      722,
      152
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      596,
      157,
      741,
      168
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
    "bbox": [
      181,
      189,
      1000,
      203
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "time to time, and the regulations promulgated thereunder..",
    "bbox": [
      112,
      208,
      591,
      223
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
    "bbox": [
      179,
      242,
      1000,
      259
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
    "bbox": [
      112,
      264,
      1000,
      277
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
    "bbox": [
      111,
      282,
      1000,
      297
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
    "bbox": [
      114,
      303,
      1000,
      316
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
    "bbox": [
      112,
      321,
      941,
      334
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
    "bbox": [
      179,
      355,
      1000,
      370
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
    "bbox": [
      111,
      375,
      1000,
      390
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
    "bbox": [
      110,
      395,
      1000,
      409
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
    "bbox": [
      112,
      414,
      1000,
      428
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
    "bbox": [
      111,
      432,
      843,
      447
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
    "bbox": [
      180,
      467,
      898,
      482
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
    "bbox": [
      181,
      504,
      820,
      517
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
    "bbox": [
      180,
      540,
      1000,
      554
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
    "bbox": [
      112,
      559,
      1000,
      574
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
    "bbox": [
      111,
      579,
      1000,
      593
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "the Product with regard to Target Professionals in the Specialty",
    "bbox": [
      111,
      597,
      647,
      612
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
    "bbox": [
      179,
      632,
      1000,
      647
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
    "bbox": [
      114,
      654,
      1000,
      666
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
    "bbox": [
      111,
      690,
      1000,
      705
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
    "bbox": [
      111,
      709,
      1000,
      724
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
    "bbox": [
      112,
      729,
      1000,
      742
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
    "bbox": [
      111,
      747,
      1000,
      761
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
    "bbox": [
      111,
      767,
      1000,
      781
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
    "bbox": [
      113,
      787,
      1000,
      799
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
    "bbox": [
      111,
      803,
      1000,
      820
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "2",
    "bbox": [
      660,
      856,
      671,
      867
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
    "bbox": [
      150,
      931,
      1000,
      941
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "bbox": [
      415,
      944,
      918,
      953
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      593,
      1000
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      610,
      141,
      722,
      152
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      596,
      157,
      741,
      168
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
    "bbox": [
      181,
      189,
      1000,
      203
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "time to time, and the regulations promulgated thereunder..",
    "bbox": [
      112,
      208,
      591,
      223
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
    "bbox": [
      179,
      242,
      1000,
      259
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
    "bbox": [
      112,
      264,
      1000,
      277
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
    "bbox": [
      111,
      282,
      1000,
      297
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
    "bbox": [
      114,
      303,
      1000,
      316
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
    "bbox": [
      112,
      321,
      941,
      334
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
    "bbox": [
      179,
      355,
      1000,
      370
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
    "bbox": [
      111,
      375,
      1000,
      390
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
    "bbox": [
      110,
      395,
      1000,
      409
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
    "bbox": [
      112,
      414,
      1000,
      428
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
    "bbox": [
      111,
      432,
      843,
      447
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
    "bbox": [
      180,
      467,
      898,
      482
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
    "bbox": [
      181,
      504,
      820,
      517
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
    "bbox": [
      180,
      540,
      1000,
      554
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
    "bbox": [
      112,
      559,
      1000,
      574
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
    "bbox": [
      111,
      579,
      1000,
      593
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "the Product with regard to Target Professionals in the Specialty",
    "bbox": [
      111,
      597,
      647,
      612
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
    "bbox": [
      179,
      632,
      1000,
      647
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
    "bbox": [
      114,
      654,
      1000,
      666
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
    "bbox": [
      111,
      690,
      1000,
      705
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
    "bbox": [
      111,
      709,
      1000,
      724
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
    "bbox": [
      112,
      729,
      1000,
      742
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
    "bbox": [
      111,
      747,
      1000,
      761
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
    "bbox": [
      111,
      767,
      1000,
      781
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
    "bbox": [
      113,
      787,
      1000,
      799
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
    "bbox": [
      111,
      803,
      1000,
      820
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "2",
    "bbox": [
      660,
      856,
      671,
      867
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
    "bbox": [
      150,
      931,
      1000,
      941
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "bbox": [
      415,
      944,
      918,
      953
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      593,
      1000
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      610,
      141,
      722,
      152
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      596,
      157,
      741,
      168
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
    "bbox": [
      181,
      189,
      1000,
      203
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "time to time, and the regulations promulgated thereunder..",
    "bbox": [
      112,
      208,
      591,
      223
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
    "bbox": [
      179,
      242,
      1000,
      259
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
    "bbox": [
      112,
      264,
      1000,
      277
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
    "bbox": [
      111,
      282,
      1000,
      297
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
    "bbox": [
      114,
      303,
      1000,
      316
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
    "bbox": [
      112,
      321,
      941,
      334
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
    "bbox": [
      179,
      355,
      1000,
      370
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
    "bbox": [
      111,
      375,
      1000,
      390
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
    "bbox": [
      110,
      395,
      1000,
      409
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
    "bbox": [
      112,
      414,
      1000,
      428
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
    "bbox": [
      111,
      432,
      843,
      447
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
    "bbox": [
      180,
      467,
      898,
      482
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
    "bbox": [
      181,
      504,
      820,
      517
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
    "bbox": [
      180,
      540,
      1000,
      554
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
    "bbox": [
      112,
      559,
      1000,
      574
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
    "bbox": [
      111,
      579,
      1000,
      593
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "the Product with regard to Target Professionals in the Specialty",
    "bbox": [
      111,
      597,
      647,
      612
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
    "bbox": [
      179,
      632,
      1000,
      647
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
    "bbox": [
      114,
      654,
      1000,
      666
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
    "bbox": [
      111,
      690,
      1000,
      705
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
    "bbox": [
      111,
      709,
      1000,
      724
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
    "bbox": [
      112,
      729,
      1000,
      742
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
    "bbox": [
      111,
      747,
      1000,
      761
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
    "bbox": [
      111,
      767,
      1000,
      781
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
    "bbox": [
      113,
      787,
      1000,
      799
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
    "bbox": [
      111,
      803,
      1000,
      820
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "2",
    "bbox": [
      660,
      856,
      671,
      867
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
    "bbox": [
      150,
      931,
      1000,
      941
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "bbox": [
      415,
      944,
      918,
      953
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      593,
      1000
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      610,
      141,
      722,
      152
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      596,
      157,
      741,
      168
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
    "bbox": [
      181,
      189,
      1000,
      203
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "time to time, and the regulations promulgated thereunder..",
    "bbox": [
      112,
      208,
      591,
      223
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
    "bbox": [
      179,
      242,
      1000,
      259
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
    "bbox": [
      112,
      264,
      1000,
      277
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
    "bbox": [
      111,
      282,
      1000,
      297
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
    "bbox": [
      114,
      303,
      1000,
      316
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
    "bbox": [
      112,
      321,
      941,
      334
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
    "bbox": [
      179,
      355,
      1000,
      370
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
    "bbox": [
      111,
      375,
      1000,
      390
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
    "bbox": [
      110,
      395,
      1000,
      409
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
    "bbox": [
      112,
      414,
      1000,
      428
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
    "bbox": [
      111,
      432,
      843,
      447
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
    "bbox": [
      180,
      467,
      898,
      482
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
    "bbox": [
      181,
      504,
      820,
      517
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
    "bbox": [
      180,
      540,
      1000,
      554
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
    "bbox": [
      112,
      559,
      1000,
      574
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
    "bbox": [
      111,
      579,
      1000,
      593
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "the Product with regard to Target Professionals in the Specialty",
    "bbox": [
      111,
      597,
      647,
      612
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
    "bbox": [
      179,
      632,
      1000,
      647
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
    "bbox": [
      114,
      654,
      1000,
      666
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
    "bbox": [
      111,
      690,
      1000,
      705
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
    "bbox": [
      111,
      709,
      1000,
      724
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
    "bbox": [
      112,
      729,
      1000,
      742
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
    "bbox": [
      111,
      747,
      1000,
      761
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
    "bbox": [
      111,
      767,
      1000,
      781
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
    "bbox": [
      113,
      787,
      1000,
      799
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
    "bbox": [
      111,
      803,
      1000,
      820
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "2",
    "bbox": [
      660,
      856,
      671,
      867
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
    "bbox": [
      150,
      931,
      1000,
      941
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "bbox": [
      415,
      944,
      918,
      953
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      593,
      1000
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      610,
      141,
      722,
      152
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      596,
      157,
      741,
      168
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
    "bbox": [
      181,
      189,
      1000,
      203
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "time to time, and the regulations promulgated thereunder..",
    "bbox": [
      112,
      208,
      591,
      223
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
    "bbox": [
      179,
      242,
      1000,
      259
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
    "bbox": [
      112,
      264,
      1000,
      277
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
    "bbox": [
      111,
      282,
      1000,
      297
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
    "bbox": [
      114,
      303,
      1000,
      316
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
    "bbox": [
      112,
      321,
      941,
      334
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
    "bbox": [
      179,
      355,
      1000,
      370
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
    "bbox": [
      111,
      375,
      1000,
      390
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
    "bbox": [
      110,
      395,
      1000,
      409
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
    "bbox": [
      112,
      414,
      1000,
      428
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
    "bbox": [
      111,
      432,
      843,
      447
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
    "bbox": [
      180,
      467,
      898,
      482
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
    "bbox": [
      181,
      504,
      820,
      517
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
    "bbox": [
      180,
      540,
      1000,
      554
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
    "bbox": [
      112,
      559,
      1000,
      574
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
    "bbox": [
      111,
      579,
      1000,
      593
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "the Product with regard to Target Professionals in the Specialty",
    "bbox": [
      111,
      597,
      647,
      612
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
    "bbox": [
      179,
      632,
      1000,
      647
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
    "bbox": [
      114,
      654,
      1000,
      666
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
    "bbox": [
      111,
      690,
      1000,
      705
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
    "bbox": [
      111,
      709,
      1000,
      724
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
    "bbox": [
      112,
      729,
      1000,
      742
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
    "bbox": [
      111,
      747,
      1000,
      761
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
    "bbox": [
      111,
      767,
      1000,
      781
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
    "bbox": [
      113,
      787,
      1000,
      799
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
    "bbox": [
      111,
      803,
      1000,
      820
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "2",
    "bbox": [
      660,
      856,
      671,
      867
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
    "bbox": [
      150,
      931,
      1000,
      941
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "bbox": [
      415,
      944,
      918,
      953
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      593,
      1000
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      610,
      141,
      722,
      152
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      596,
      157,
      741,
      168
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
    "bbox": [
      181,
      189,
      1000,
      203
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "time to time, and the regulations promulgated thereunder..",
    "bbox": [
      112,
      208,
      591,
      223
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
    "bbox": [
      179,
      242,
      1000,
      259
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
    "bbox": [
      112,
      264,
      1000,
      277
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
    "bbox": [
      111,
      282,
      1000,
      297
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
    "bbox": [
      114,
      303,
      1000,
      316
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
    "bbox": [
      112,
      321,
      941,
      334
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
    "bbox": [
      179,
      355,
      1000,
      370
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
    "bbox": [
      111,
      375,
      1000,
      390
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
    "bbox": [
      110,
      395,
      1000,
      409
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
    "bbox": [
      112,
      414,
      1000,
      428
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
    "bbox": [
      111,
      432,
      843,
      447
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
    "bbox": [
      180,
      467,
      898,
      482
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
    "bbox": [
      181,
      504,
      820,
      517
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
    "bbox": [
      180,
      540,
      1000,
      554
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
    "bbox": [
      112,
      559,
      1000,
      574
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
    "bbox": [
      111,
      579,
      1000,
      593
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "the Product with regard to Target Professionals in the Specialty",
    "bbox": [
      111,
      597,
      647,
      612
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
    "bbox": [
      179,
      632,
      1000,
      647
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
    "bbox": [
      114,
      654,
      1000,
      666
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
    "bbox": [
      111,
      690,
      1000,
      705
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
    "bbox": [
      111,
      709,
      1000,
      724
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
    "bbox": [
      112,
      729,
      1000,
      742
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
    "bbox": [
      111,
      747,
      1000,
      761
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
    "bbox": [
      111,
      767,
      1000,
      781
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
    "bbox": [
      113,
      787,
      1000,
      799
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
    "bbox": [
      111,
      803,
      1000,
      820
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "2",
    "bbox": [
      660,
      856,
      671,
      867
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
    "bbox": [
      150,
      931,
      1000,
      941
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "bbox": [
      415,
      944,
      918,
      953
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      593,
      1000
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      610,
      141,
      722,
      152
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      596,
      157,
      741,
      168
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
    "bbox": [
      181,
      189,
      1000,
      203
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "time to time, and the regulations promulgated thereunder..",
    "bbox": [
      112,
      208,
      591,
      223
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
    "bbox": [
      179,
      242,
      1000,
      259
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
    "bbox": [
      112,
      264,
      1000,
      277
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
    "bbox": [
      111,
      282,
      1000,
      297
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
    "bbox": [
      114,
      303,
      1000,
      316
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
    "bbox": [
      112,
      321,
      941,
      334
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
    "bbox": [
      179,
      355,
      1000,
      370
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
    "bbox": [
      111,
      375,
      1000,
      390
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
    "bbox": [
      110,
      395,
      1000,
      409
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
    "bbox": [
      112,
      414,
      1000,
      428
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
    "bbox": [
      111,
      432,
      843,
      447
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
    "bbox": [
      180,
      467,
      898,
      482
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
    "bbox": [
      181,
      504,
      820,
      517
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
    "bbox": [
      180,
      540,
      1000,
      554
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
    "bbox": [
      112,
      559,
      1000,
      574
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
    "bbox": [
      111,
      579,
      1000,
      593
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "the Product with regard to Target Professionals in the Specialty",
    "bbox": [
      111,
      597,
      647,
      612
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
    "bbox": [
      179,
      632,
      1000,
      647
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
    "bbox": [
      114,
      654,
      1000,
      666
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
    "bbox": [
      111,
      690,
      1000,
      705
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
    "bbox": [
      111,
      709,
      1000,
      724
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
    "bbox": [
      112,
      729,
      1000,
      742
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
    "bbox": [
      111,
      747,
      1000,
      761
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
    "bbox": [
      111,
      767,
      1000,
      781
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
    "bbox": [
      113,
      787,
      1000,
      799
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
    "bbox": [
      111,
      803,
      1000,
      820
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "2",
    "bbox": [
      660,
      856,
      671,
      867
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
    "bbox": [
      150,
      931,
      1000,
      941
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "bbox": [
      415,
      944,
      918,
      953
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      593,
      1000
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      610,
      141,
      722,
      152
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      596,
      157,
      741,
      168
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
    "bbox": [
      181,
      189,
      1000,
      203
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "time to time, and the regulations promulgated thereunder..",
    "bbox": [
      112,
      208,
      591,
      223
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
    "bbox": [
      179,
      242,
      1000,
      259
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
    "bbox": [
      112,
      264,
      1000,
      277
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
    "bbox": [
      111,
      282,
      1000,
      297
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
    "bbox": [
      114,
      303,
      1000,
      316
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
    "bbox": [
      112,
      321,
      941,
      334
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
    "bbox": [
      179,
      355,
      1000,
      370
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
    "bbox": [
      111,
      375,
      1000,
      390
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
    "bbox": [
      110,
      395,
      1000,
      409
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
    "bbox": [
      112,
      414,
      1000,
      428
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
    "bbox": [
      111,
      432,
      843,
      447
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
    "bbox": [
      180,
      467,
      898,
      482
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
    "bbox": [
      181,
      504,
      820,
      517
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
    "bbox": [
      180,
      540,
      1000,
      554
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
    "bbox": [
      112,
      559,
      1000,
      574
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
    "bbox": [
      111,
      579,
      1000,
      593
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "the Product with regard to Target Professionals in the Specialty",
    "bbox": [
      111,
      597,
      647,
      612
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
    "bbox": [
      179,
      632,
      1000,
      647
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
    "bbox": [
      114,
      654,
      1000,
      666
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
    "bbox": [
      111,
      690,
      1000,
      705
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
    "bbox": [
      111,
      709,
      1000,
      724
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
    "bbox": [
      112,
      729,
      1000,
      742
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
    "bbox": [
      111,
      747,
      1000,
      761
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
    "bbox": [
      111,
      767,
      1000,
      781
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
    "bbox": [
      113,
      787,
      1000,
      799
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
    "bbox": [
      111,
      803,
      1000,
      820
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "2",
    "bbox": [
      660,
      856,
      671,
      867
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
    "bbox": [
      150,
      931,
      1000,
      941
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "bbox": [
      415,
      944,
      918,
      953
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      593,
      1000
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "ARTICLE 1",
    "bbox": [
      610,
      141,
      722,
      152
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "DEFINITIONS",
    "bbox": [
      596,
      157,
      741,
      168
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "1.1 \"Act\"' shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C. s 301 et seq., as it may be amended from",
    "bbox": [
      181,
      189,
      1000,
      203
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "time to time, and the regulations promulgated thereunder..",
    "bbox": [
      112,
      208,
      591,
      223
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "1.2 \"Adverse Event\"' shall mean any untoward medical occurrence in a patient or clinical investigation subject who is",
    "bbox": [
      179,
      242,
      1000,
      259
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "administered the Product, but which does not necessarily have a causal relationship with the treatment for which the Product is",
    "bbox": [
      112,
      264,
      1000,
      277
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "used. An \"Adverse Event' can include any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or",
    "bbox": [
      111,
      282,
      1000,
      297
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "disease temporally associated with the use of the Product, whether or not related to the Product. A pre-existing condition that",
    "bbox": [
      114,
      303,
      1000,
      316
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "worsened in severity after administration of the Product would be considered an \"Adverse Event'.",
    "bbox": [
      112,
      321,
      941,
      334
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "1.3 \"Affiliate\" shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by",
    "bbox": [
      179,
      355,
      1000,
      370
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses the",
    "bbox": [
      111,
      375,
      1000,
      390
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of",
    "bbox": [
      110,
      395,
      1000,
      409
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "fifty percent (50%) or more (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a",
    "bbox": [
      112,
      414,
      1000,
      428
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "particular jurisdiction) of the voting securities of such Person, by contract or otherwise..",
    "bbox": [
      111,
      432,
      843,
      447
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "1.4 \"Agreement' shall have the meaning set forth in the preamble to this Agreement..",
    "bbox": [
      180,
      467,
      898,
      482
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "1.5 \"Alliance Managers\"' shall have the meaning set forth in Section 4.1.4..",
    "bbox": [
      181,
      504,
      820,
      517
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "1.6 \"Alternate Product' shall mean a pharmaceutical product that is commercialized by Valeant or its Affiliates in the",
    "bbox": [
      180,
      540,
      1000,
      554
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "Territory and that is part of the Salix business segment of Valeant's parent company, Bausch Health Companies, Inc. (or, in the",
    "bbox": [
      112,
      559,
      1000,
      574
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "event that such business segments are restructured, that is part of the Salix business unit), and which product is complementary to",
    "bbox": [
      111,
      579,
      1000,
      593
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "the Product with regard to Target Professionals in the Specialty",
    "bbox": [
      111,
      597,
      647,
      612
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "1.7 \"Applicable Laws\" shall mean all applicable statutes, ordinances, regulations, codes, rules, or orders of any kind",
    "bbox": [
      179,
      632,
      1000,
      647
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "whatsoever of any Governmental Authority in the Territory pertaining to any of the activities and obligations contemplated by this",
    "bbox": [
      114,
      654,
      1000,
      666
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "Kickback Statute (42 U.S.C. s 1320a-7b et seq.), the Health Insurance Portability and Accountability Act of 1996, the Federal",
    "bbox": [
      111,
      690,
      1000,
      705
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "False Claims Act (31 U.S.C. $S 3729-3733) (and applicable state false claims acts), the Physician Payments Sunshine Act, the",
    "bbox": [
      111,
      709,
      1000,
      724
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "Code, the Department of Health and Human Services Office of Inspector General Compliance Program Guidance for",
    "bbox": [
      112,
      729,
      1000,
      742
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "Pharmaceutical Manufacturers, released April 2003, the Antifraud and Abuse Amendment to the Social Security Act, the",
    "bbox": [
      111,
      747,
      1000,
      761
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "American Medical Association guidelines on gifts to physicians, generally accepted standards of good clinical practices adopted by",
    "bbox": [
      111,
      767,
      1000,
      781
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "current FDA regulations, as well as any state laws and regulations (i) impacting the promotion of pharmaceutical products, (ii)",
    "bbox": [
      113,
      787,
      1000,
      799
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "governing the provision of meals and other gifts to medical professionals, including pharmacists, or (ii) governing consumer",
    "bbox": [
      111,
      803,
      1000,
      820
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "2",
    "bbox": [
      660,
      856,
      671,
      867
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "CHIHI NHHN SRH LRNIHXH SIHL IO NOISIIA HLIIHNRR R [***] CHLVNNISHE HIV SNOISSIMR LSHNOHN ARITRILNHERINRE V OL PNHNNNP",
    "bbox": [
      150,
      931,
      1000,
      941
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "bbox": [
      415,
      944,
      918,
      953
    ],
    "label": 36,
    "category": "Liquidated Damages"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      593,
      1000
    ],
    "label": 36,
    "category": "Liquidated Damages"
  }
]